Cabot (NYSE:CBT) Updates FY 2026 Earnings Guidance

Cabot (NYSE:CBT) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 6.150-6.450 for the period, compared to the consensus EPS estimate of 6.320. The company issued revenue guidance of -.

Cabot Stock Performance

CBT traded up $1.98 on Monday, hitting $90.00. 550,871 shares of the stock traded hands, compared to its average volume of 473,504. The business has a fifty day moving average price of $87.89 and a two-hundred day moving average price of $79.43. The company has a current ratio of 1.45, a quick ratio of 0.96 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $4.65 billion, a PE ratio of 17.01, a P/E/G ratio of 11.46 and a beta of 0.83. Cabot has a 52 week low of $58.33 and a 52 week high of $94.53.

Cabot (NYSE:CBT) last announced its quarterly earnings data on Monday, August 3rd. The specialty chemicals company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.65 by $0.02. The company had revenue of $982.00 million for the quarter, compared to analyst estimates of $943.16 million. Cabot had a return on equity of 21.33% and a net margin of 7.97%.Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. On average, research analysts predict that Cabot will post 6.35 EPS for the current fiscal year.

Cabot Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.4725 dividend. This represents a $1.89 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Friday, August 28th. Cabot’s payout ratio is 35.73%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on CBT shares. Wall Street Zen downgraded shares of Cabot from a “buy” rating to a “hold” rating in a report on Saturday. Truist Financial started coverage on Cabot in a research note on Monday, June 8th. They issued a “buy” rating and a $98.00 price objective on the stock. UBS Group increased their price objective on Cabot from $81.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, May 8th. Mizuho boosted their target price on shares of Cabot from $80.00 to $90.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Finally, JPMorgan Chase & Co. increased their target price on shares of Cabot from $68.00 to $70.00 and gave the stock an “underweight” rating in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cabot has an average rating of “Hold” and an average price target of $85.80.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CBT. NewEdge Advisors LLC raised its position in shares of Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock worth $82,000 after acquiring an additional 947 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after purchasing an additional 108,645 shares during the last quarter. Empowered Funds LLC lifted its position in Cabot by 102.6% during the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after purchasing an additional 14,260 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cabot by 3.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after purchasing an additional 4,048 shares during the period. Finally, Geneos Wealth Management Inc. grew its position in shares of Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after buying an additional 364 shares during the period. Institutional investors and hedge funds own 93.18% of the company’s stock.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.